Novadaq Technologies Upgraded to Neutral at Zacks (NVDQ)
Novadaq Technologies (NASDAQ:NVDQ) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued to investors on Monday, Stock Ratings News reports. The firm currently has a $17.40 price objective on the stock. Zacks‘ price target indicates a potential upside of 2.41% from the stock’s previous close.
Shares of Novadaq Technologies (NASDAQ:NVDQ) traded down 2.65% during mid-day trading on Monday, hitting $16.54. The stock had a trading volume of 242,647 shares. Novadaq Technologies has a one year low of $8.29 and a one year high of $17.29. The stock’s 50-day moving average is $15.17 and its 200-day moving average is $13.44. The company’s market cap is $800.6 million.
Novadaq Technologies (NASDAQ:NVDQ) last announced its earnings results on Thursday, August 1st. The company reported ($0.05) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.02) by $0.03. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $7.89 million. During the same quarter last year, the company posted ($0.03) earnings per share. Novadaq Technologies’s revenue was up 50.0% compared to the same quarter last year.
A number of other analysts have also recently weighed in on NVDQ. Analysts at Feltl & Co. raised their price target on shares of Novadaq Technologies from $15.25 to $18.50 in a research note to investors on Friday, September 27th. They now have a “buy” rating on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Novadaq Technologies in a research note to investors on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the stock. Novadaq Technologies has a consensus rating of “Hold” and a consensus target price of $13.61.
Novadaq Technologies Inc develops and commercializes medical imaging and therapeutic devices for use in the operating room.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.